Virtue
Chris Parmentier, Virtue
“We have been working with RNA for several years. They are responsive, reliable, understand the nuances of our business and help us with modeling expertise that exceeds the capabilities within our corporate organization. We value them as an ecosystem partner and as a true extension of our operating team.”
Supporting the Entire Life Cycle: Biotech Company
RNA Advisors Supported a Biotech Company from Inception through IPO through M&A
Bruce Peacock
“I’ve worked with the RNA team on a number of valuation matters, large and small. These guys know their stuff. Whether using them to assist with large licensing transaction negotiations to simple tax and financial reporting work, they understand and they deliver.”
Fairness Opinion: Distressed M&A
Private Company Under Financial Distress Considering Transaction Alternatives
Stig Hansen, Kimia Therapeutics
“I’ve worked with the RNA team for over a decade across my current and previous companies. They are our go to valuation firm for valuation because they know the industry, are responsive and understand the nuances that drive transactions just as much as accounting.”
Fairness Opinion: SPAC Target Company Valuation in Biotech
SPAC Seeks Target Company Valuation in Merger Consideration Transaction
Fairness Opinion: De-SPAC Transaction for Inflammatory Disorders Therapeutics Company
SPAC Seeks Independent Valuation of Target
Fairness Opinion: De-SPAC Transaction for T-Cell Therapeutics Company
SPAC Seeks Independent Valuation of Target Company in T-Cell Therapeutics
